Article Text

Download PDFPDF
Arthroscopic partial meniscectomy versus exercise therapy for degenerative meniscal tears: 10-year follow-up of the OMEX randomised controlled trial
  1. Bjørnar Berg1,2,
  2. Ewa M Roos3,
  3. Martin Englund4,
  4. Nina Jullum Kise5,
  5. Lars Engebretsen1,6,
  6. Cathrine Nørstad Eftang7,
  7. May Arna Risberg1,8
  1. 1Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway
  2. 2Centre for Intelligent Musculoskeletal Health, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway
  3. 3Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark
  4. 4Clinical Epidemiology Unit, Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
  5. 5Department of Orthopedic Surgery, Martina Hansens Hospital, Sandvika, Norway
  6. 6Oslo Sports Trauma Research Center, Norwegian School of Sports Sciences, Oslo, Norway
  7. 7Global Clinical and Regulatory Affairs Medical, DNV Product Assurance AS, Høvik, Norway
  8. 8Department of Sports Medicine, Norwegian School of Sports Sciences, Oslo, Norway
  1. Correspondence to Dr Bjørnar Berg; bjornarb{at}oslomet.no

Abstract

Objective To evaluate radiographic knee osteoarthritis (OA) progression, development of knee OA, patient-reported outcomes and knee muscle strength at 10-year follow-up after arthroscopic partial meniscectomy (APM) or exercise therapy for degenerative meniscal tears.

Methods Randomised controlled trial including 140 participants, with a degenerative meniscal tear and no or minimal radiographic OA changes. Participants were randomised to either APM or 12 weeks of exercise therapy (1:1 ratio). The primary outcome was knee OA progression assessed by the Osteoarthritis Research Society International (OARSI) atlas sum score (sum of medial and lateral compartment joint space narrowing and osteophyte score). Secondary outcomes included incidence of radiographic and symptomatic knee OA, patient-reported pain and knee function and isokinetic knee muscle strength.

Results The adjusted mean difference in change in the OARSI sum score was 0.39 (95% CI −0.19 to 0.97), with more progression in the APM group. The incidence of radiographic knee OA was 23% in the APM group and 20% in the exercise group (adjusted risk difference 3% (95% CI −13% to 19%)). No clinically relevant differences were found in patient-reported outcomes or isokinetic knee muscle strength.

Conclusion No differences in radiographic knee OA progression and comparable rates of knee OA development were observed 10 years following APM and exercise therapy for degenerative meniscal tears. Both treatments were associated with improved patient-reported pain and knee function.

Trial registration number NCT01002794.

  • arthroscopy
  • exercise

Data availability statement

Data are available on reasonable request.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available on reasonable request.

View Full Text

Footnotes

  • X @ewa_roos, @dr_englund, @larsengebretsen

  • Contributors BB, EMR, ME and MAR conceived and designed the study. BB, NJK, LE and MAR contributed to the acquisition of data. All authors contributed to the analysis or interpretation of data. BB wrote the initial draft. All authors revised the draft critically for important intellectual content and approved the final version. BB acts as guarantor and takes responsibility for the integrity of the data and the accuracy of the data analysis. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

  • Funding This study was funded by grants from the South-Eastern Norway Regional Health Authority (grant number 2018023); Sophies Minde Ortopedi; Swedish Rheumatism Association; Swedish Research Council; Governmental Funding of Clinical Research within National Health Service (ALF); Foundation for Support to People with Movement Disability in Skåne; Region of Southern Denmark and the Danish Rheumatism Association.

  • Disclaimer The funders had no role in the design and conduct of the study; collection, analysis and interpretation of data; preparation, review or approval of the manuscript or decision to submit the manuscript for publication.

  • Competing interests BB reports grants from the South-Eastern Norway Regional Health Authority, during the conduct of this study. EMR is the copyright holder of Knee injury and Osteoarthritis Outcome Score (KOOS) and several other patient-reported outcome measures, and co-founder of the Good Life with Osteoarthritis in Denmark (GLA:D), a not-for-profit initiative to implement clinical guidelines in primary care hosted by University of Southern Denmark. ME reports consultancy for Grünenthal Sweden AB. MAR is the co-founder of the AktivA (www.aktivmedartrose.no) in Norway, a not-for-profit initiative to implement evidence-based guidelines hosted by the Oslo University Hospital. All other authors declare no competing interests.

  • Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the 'Methods' section for further details.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.